TURNSTONE BIOLOGICS CORP (TSBX)
US90042W1009 - Common Stock
Overall TSBX gets a fundamental rating of 2 out of 10. We evaluated TSBX against 573 industry peers in the Biotechnology industry. The financial health of TSBX is average, but there are quite some concerns on its profitability. TSBX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year TSBX has reported negative net income.
In the past year TSBX has reported a negative cash flow from operations.
1.2 Ratios
TSBX has a Return On Assets of -97.17%. This is in the lower half of the industry: TSBX underperforms 76.06% of its industry peers.
TSBX's Return On Equity of -125.05% is in line compared to the rest of the industry. TSBX outperforms 40.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -97.17% | ||
| ROE | -125.05% | ||
| ROIC | N/A |
ROA(3y)-24.7%
ROA(5y)N/A
ROE(3y)-32.05%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for TSBX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TSBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TSBX has been increased compared to 1 year ago.
TSBX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -6.03, we must say that TSBX is in the distress zone and has some risk of bankruptcy.
TSBX has a Altman-Z score of -6.03. This is in the lower half of the industry: TSBX underperforms 66.90% of its industry peers.
TSBX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.03 |
ROIC/WACCN/A
WACC10.21%
2.3 Liquidity
A Current Ratio of 4.38 indicates that TSBX has no problem at all paying its short term obligations.
The Current ratio of TSBX (4.38) is comparable to the rest of the industry.
TSBX has a Quick Ratio of 4.38. This indicates that TSBX is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.38, TSBX perfoms like the industry average, outperforming 50.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.38 | ||
| Quick Ratio | 4.38 |
3. Growth
3.1 Past
TSBX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -241.67%.
TSBX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -73.66%.
EPS 1Y (TTM)-241.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.83%
Revenue 1Y (TTM)-73.66%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
TSBX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.89% yearly.
Based on estimates for the next years, TSBX will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y33.92%
EPS Next 2Y25.7%
EPS Next 3Y6.89%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
TSBX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TSBX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.7%
EPS Next 3Y6.89%
5. Dividend
5.1 Amount
TSBX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TURNSTONE BIOLOGICS CORP
NASDAQ:TSBX (9/18/2024, 8:00:03 PM)
After market: 0.6399 -0.04 (-5.91%)0.6801
+0.03 (+4.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap15.73M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -97.17% | ||
| ROE | -125.05% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.38 | ||
| Quick Ratio | 4.38 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-241.67%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y33.92%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-73.66%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y